Search Results - "Bentley, Jane H."

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial by Roufosse, Florence, Kahn, Jean-Emmanuel, Rothenberg, Marc E., Wardlaw, Andrew J., Klion, Amy D., Kirby, Suyong Yun, Gilson, Martyn J., Bentley, Jane H., Bradford, Eric S., Yancey, Steven W., Steinfeld, Jonathan, Gleich, Gerald J.

“…Anti–IL-5 therapy is a potential treatment for patients with hypereosinophilic syndrome (HES), although its clinical efficacy is unclear. We sought to…”
Get full text

Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study by Jenkins, R Gisli, PhD, Simpson, Juliet K, PhD, Saini, Gauri, MD, Bentley, Jane H, PhD, Russell, Anne-Marie, MSc, Braybrooke, Rebecca, RGN, Molyneaux, Philip L, MD, McKeever, Tricia M, PhD, Wells, Athol U, MD, Flynn, Aiden, PhD, Hubbard, Richard B, Prof, Leeming, Diana J, PhD, Marshall, Richard P, PhD, Karsdal, Morten A, PhD, Lukey, Pauline T, PhD, Maher, Toby M, Dr

“…Summary Background Idiopathic pulmonary fibrosis, a progressive and inevitably fatal disorder, has a highly variable clinical course. Biomarkers that reflect…”
Get full text

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome by Pane, Fabrizio, Lefevre, Guillaume, Kwon, Namhee, Bentley, Jane H., Yancey, Steven W., Steinfeld, Jonathan

“…In patients with hypereosinophilic syndrome (HES), mepolizumab reduces the incidence of HES-related clinical signs and symptoms (flares). However, reports…”
Get full text

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome by Roufosse, Florence, Butterfield, Joseph, Steinfeld, Jonathan, Bentley, Jane H, von Maltzahn, Robyn, Kwon, Namhee, Nelsen, Linda

“…Hypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage…”
Get full text

Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics by Jayne, David R W, Terrier, Benjamin, Hellmich, Bernhard, Khoury, Paneez, Baylis, Lee, Bentley, Jane H, Steinfeld, Jonathan, Yancey, Steven W, Kwon, Namhee, Wechsler, Michael E, Akuthota, Praveen

“…The Mepolizumab in Relapsing or Refractory EGPA (MIRRA) trial (GSK ID: 115921/NCT02020889) demonstrated that mepolizumab increased remission time and reduced…”
Get full text

Usability of mepolizumab single-use prefilled autoinjector for patient self-administration by Bernstein, David, Pavord, Ian D., Chapman, Kenneth R., Follows, Richard, Bentley, Jane H., Pouliquen, Isabelle, Bradford, Eric

“…Objective: To evaluate usability of mepolizumab as a liquid drug product self-administered via a single-use prefilled autoinjector (AI) by patients with severe…”
Get full text

Usability of mepolizumab single-use prefilled syringe for patient self-administration by Bel, Elisabeth H., I. Bernstein, David, Bjermer, Leif, Follows, Richard, Bentley, Jane H., Pouliquen, Isabelle, Bradford, Eric

“…Objective: A liquid mepolizumab formulation in a single-use prefilled syringe (PFS) is under development. We evaluated the usability of mepolizumab…”
Get full text

The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes by de Lemos, James A, Morrow, David A, Bentley, Jane H, Omland, Torbjørn, Sabatine, Marc S, McCabe, Carolyn H, Hall, Christian, Cannon, Christopher P, Braunwald, Eugene

“…There may be neurohormonal activation in patients at high risk for death. Brain (B-type) natriuretic peptide is a 32-amino-acid neurohormone synthesized in…”
Get full text

Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study by Gleich, Gerald J., Roufosse, Florence, Chupp, Geoffrey, Faguer, Stanislas, Walz, Bastian, Reiter, Andreas, Yancey, Steven W., Bentley, Jane H., Steinfeld, Jonathan, García, Gabriel Ricardo, Pascale, Pablo, Wehbe, Luis, Blockmans, Daniël, Roufosse, Florence, Antila, Martti Anton, Blanco, Daniela, Francisco Pez, Andreia Luisa, Faguer, Stanislas, Kahn, Jean-Emmanuel, Lefévre, Guillaume, Neel, Antoine, Kern, Peter M., Reiter, Andreas J., Walz, Bastian, Welte, Tobias, Pane, Fabrizio, Vannucchi, Alessandro M., Cerino-Javier, Ruth, Hernández-Colín, Dante D., Valdéz-López, Héctor Glenn, Kupryś-Lipińska, Izabela R., Musial, Jacek, Mihaly, Eniko, Popov, Viola Maria, Ivanov, Vladimir, Tsyba, Nikolay, Cid, Maria C., Fox, Maria Laura, Santillana, Guillermo Sanz, Wardlaw, Andrew J., Akuthota, Praveen, Butterfield, Joseph H., Chupp, Geoffrey L., Gleich, Gerald J., Jhaveri, Devi, Rothenberg, Marc E.

“…A double-blind, placebo-controlled, phase III study (200622) showed that mepolizumab reduces disease flares for patients with uncontrolled…”
Get full text

The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial by Shabbir, Shaila, Pouliquen, Isabelle J., Bentley, Jane H., Bradford, Eric S., C. Kaisermann, Morrys, Albayaty, Muna

“…This study compared the pharmacokinetic (PK) profile of a new liquid formulation of mepolizumab with the established lyophilized formulation. In this…”
Get full text

Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris by Cannon, Christopher P, McCabe, Carolyn H, Wilcox, Robert G, Bentley, Jane H, Braunwald, Eugene

“…We observed in a study of 7,651 patients with acute coronary syndromes that a white blood cell (WBC) count of greater than 10,000 was associated with increased…”
Get full text

The effect of GSK2190915, a 5-lipoxygenase-activating protein inhibitor, on exercise-induced bronchoconstriction by Kent, Sandra E, Bentley, Jane H, Miller, David, Sterling, Richard, Menendez, Rogelio, Tarpay, Martha, Pearlman, David S, Norris, Virginia

“…Exercise-induced bronchoconstriction (EIB) describes the condition whereby exercise causes airflow obstruction that lasts for up to 90 minutes without…”
Get more information

Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose-response study by Singh, Dave, Boyce, Malcolm, Norris, Virginia, Kent, Sandra E, Bentley, Jane H

“…GSK2190915, a 5-lipoxygenase activating protein inhibitor, inhibits the production of cysteinyl leukotrienes and leukotriene B4 and…”
Get full text

Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? by Kovar, David, Cannon, Christopher P., Bentley, Jane H., Charlesworth, Andrew, Rogers, William J.

“…Background: Lower admission heart rate (HR) is known to predict favorable outcome in ST‐elevation acute myocardial infarction. However, there are limited…”
Get full text

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype by Terrier, Benjamin, Jayne, David R.W., Hellmich, Bernhard, Bentley, Jane H., Steinfeld, Jonathan, Yancey, Steven W., Kwon, Namhee, Akuthota, Praveen, Khoury, Paneez, Baylis, Lee, Wechsler, Michael E.

“…Objective To evaluate mepolizumab's efficacy in eosinophilic granulomatosis with polyangiitis (EGPA) with and without a vasculitic phenotype. Methods The MIRRA…”
Get full text

Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2I909I5: a dose-response study by Singh, Dave, Boyce, Malcolm, Norris, Virginia, Kent, Sandra E, Bentley, Jane H

“…Background: GSK2190915, a 5-lipoxygenase activating protein inhibitor, inhibits the production of cysteinyl leukotrienes and leukotriene B4 and…”
Get full text

The prognostic valve of B-type natriuretic peptide in patients with acute coronary syndromes by de Lemos, James A, Morrow, David A, Bentley, Jane H, Omland, Torbjørn, Sabatine, Marc S, McCabe, Carolyn H, Hall, Christian, Cannon, Christopher P, Braunwald, Eugene

“…Background Brain (B-type) natriuretic peptide is a neurohormone synthesized predominantly in ventricular myocardium. Although the circulating level of this…”
Get full text